hrp0095p1-510 | Growth and Syndromes | ESPE2022

Temple syndrome: clinical findings and body composition

Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is an imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder and phenotypic features include pre- and postnatal growth retardation, hypotonia, feeding difficulties, precocious puberty, short stature and truncal obesity.Methods: Thi...

hrp0092p1-366 | GH and IGFs (2) | ESPE2019

Glomerular Filtration Rate in Young Adults Born SGA: A 5-Year Longitudinal Study after Cessation of GH Treatment.

Goedegebuure Wesley , Kerkhof Gerthe , Hokken-Koelega Anita

Background: GH treatment increases glomerular filtration rate (GFR), as serum IGF-I stimulates the renin-angiotensin system. Data on longitudinal changes in GFR after cessation of GH treatment in young adults born small for gestational age (SGA) are not available. It is essential to ascertain longitudinal data after cessation of GH treatment, to evaluate the possible long-term effects of higher serum IGF-I levels during childhood treatment on adult GFR.<p ...

hrp0094p2-294 | Growth and syndromes (to include Turner syndrome) | ESPE2021

The spectrum of the Prader-Willi-like pheno- and genotype

Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita ,

Background/aims: Prader-Willi syndrome (PWS) is a rare genetic syndrome, caused by the loss of expression of the paternal chromosome 15q11-q13 region. Over the past years, many cases of patients with characteristics similar to PWS, but without the typical genetic aberration of the 15q11-q13 region, have been described. These patients are often labelled as Prader-Willi-like (PWL). PWL is an as-yet poorly defined syndrome, potentially affecting a significant num...

hrp0095p1-310 | Growth and Syndromes | ESPE2022

The Prader-Willi phenotype and atypical 15q11.2-q13 deletions

Grootjen Lionne , Juriaans Alicia , Kerkhof Gerthe , Hokken-Koelega Anita

Introduction: Prader-Willi syndrome (PWS) is a rare genetic disorder resulting from the lack of expression of the PWS region (locus q11-q13) on the paternally derived chromosome 15. Either a paternal deletion of the PWS region (50%), a maternal uniparental disomy (mUPD; 43%), an imprinting defect (4.1%) or translocation (<1%) can lead to PWS. Deletions are almost always de novo and manifest either as a large type I or a smaller type II deletion. In more rar...

hrp0095p1-505 | Growth and Syndromes | ESPE2022

The effects of one year of growth hormone treatment on growth and body composition in patients with Temple syndrome

Juriaans Alicia , Trueba-Timmermans Demi , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is a rare imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder. Some patients with TS14 are treated with growth hormone (GH). However, evidence for the effectiveness of GH-treatment in patients with TS14 is very limited.Methods: ...

hrp0095p1-278 | Fat, Metabolism and Obesity | ESPE2022

e-REC Capturing The Occurrence and Burden Of COVID-19 Infections In People With Rare Genetic Obesity Disorders

Kerkhof Gerthe , Wabitsch Martin , Bryce Jillian , Johannsson Gudmundur , Ahmed Faisal , van den Akker Erica

Introduction: Following the onset of the COVID-19 pandemic in spring 2020, the European Registries For Rare Endocrine Conditions (EuRRECa), which is a collaboration between Endo-ERN, ESPE and ESE provided the possibility for registration of cases. Obesity is a risk factor for severe COVID-19 disease course in adults. In children and adolescents, COVID-19 disease course is much milder, but has also been identified as risk factor. As rare genetic obesity disorde...

hrp0086fc8.5 | Growth: Clinical | ESPE2016

Longitudinal Study on Body Composition, Insulin Sensitivity and β-cell Function in SGA Adults from Stop of Long-term GH Treatment until 5 Years after Stop

van der Steen Manouk , Kerkhof Gerthe F. , Hokken-Koelega Anita C.S.

Background: GH treatment results in a decrease in fat mass (FM) and insulin sensitivity (Si), and an increase in lean body mass (LBM). Only limited data are available on the longitudinal changes after discontinuation of GH treatment in SGA adults, aged 21 years.Objective and hypotheses: To assess longitudinal changes in body composition (BC) and glucose homeostasis after stop of GH treatment in SGA adults.Method: 197 previously GH-...

hrp0084p2-449 | Growth | ESPE2015

Risk for Non-Alcoholic Fatty Liver Disease in Young Adults Born Preterm

Breij Laura M , Kerkhof Gerthe F , Hokken-Koelega Anita C S

Background: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. Accelerated catch-up in weight during infancy in subjects born term has been associated with increased risk for NAFLD in adulthood, but this association has not been studied in subjects born preterm.Objective and hypotheses: To investigate the associations of birth weight, gain in weight for length and accelerated catch-up in weight in the...

hrp0094p1-165 | Growth B | ESPE2021

Effects of age of start growth hormone treatment in children with Prader-Willi syndrome: The earlier the better?

Grootjen Lionne , Timmermans Demi , Damen Layla , Kerkhof Gerthe , Hokken-Koelega Anita ,

Context: Clinical findings characterizing PWS are muscular hypotonia, abnormal body composition, developmental delay, behavioral problems, hyperphagia with obesity when food intake is not restricted and short stature. Endocrine problems are described, like hypogonadism, hypothyroidism and adrenal insufficiency and growth hormone (GH) deficiency. Hypothalamic dysfunction may be responsible for many features of PWS. Randomized controlled studies showed that GH t...

hrp0098p1-164 | Growth and Syndromes 2 | ESPE2024

Prevalence of failure to thrive in infants with Prader-Willi syndrome and the long-term effects of GH-treatment

Trueba-Timmermans Demi , Grootjen Lionne , Kerkhof Gerthe , Rings Edmond , Hokken-Koelega Anita

Context: In the newborn period, failure to thrive (FTT) with feeding difficulties and severe hypotonia are prominent in Prader-Willi syndrome (PWS). Despite the low weight, abnormal body composition is already present at birth in both children with FTT and those without. Limited studies reported the prevalence of FTT in infants with PWS and it has not yet been described whether GH-treatment has different effects in infants with FTT compared to those without.</...